TMT and Western blot analyses revealed that NOL6 knockdown suppressed MCM3 and MCM7 expression.<h4>Conclusion</h4>This study demonstrated that NOL6 functions as an oncogene that facilitates CRC progression, suggesting its potential role as a therapeutic target for CRC management. The gene discussed is MCM7; the disease is colorectal carcinoma.